Impact of novel glucose-lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta-analysis of randomised placebo-controlled trials.
Diabetic medicine : a journal of the British Diabetic Association（2023）
摘要
GLP-1RAs showed improvements in self-reported outcomes of physical function. However, there is limited evidence to draw definitive conclusions especially because of lack of studies exploring the impact of SGLT2i and DPP4i on physical function. There is a need for dedicated trials to establish the association between novel agents and physical function.
更多查看译文
关键词
dipeptidyl peptidase-4 inhibitors,glucagon-like peptide-1 receptor agonists,glucose-lowering therapies,physical function,sodium-glucose co-transporter-2 inhibitors,type 2 diabetes
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要